Copyright Reports & Markets. All rights reserved.

Global Tubulin Inhibitors for Breast Cancer Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Tubulin Inhibitors for Breast Cancer Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Eribulin
      • 1.4.3 Ixabepilone
      • 1.4.4 Docetaxel
      • 1.4.5 Trastuzumab Emtansine
      • 1.4.6 Utidelone
      • 1.4.7 Paclitaxel
      • 1.4.8 Liposome Paclitaxel
      • 1.4.9 Protein-bound Paclitaxel
    • 1.5 Market by Application
      • 1.5.1 Global Tubulin Inhibitors for Breast Cancer Market Share by Application (2014-2025)
      • 1.5.2 Hospital
      • 1.5.3 Clinic
      • 1.5.4 Drug Center
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Tubulin Inhibitors for Breast Cancer Market Size
    • 2.2 Tubulin Inhibitors for Breast Cancer Growth Trends by Regions
      • 2.2.1 Tubulin Inhibitors for Breast Cancer Market Size by Regions (2014-2025)
      • 2.2.2 Tubulin Inhibitors for Breast Cancer Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Tubulin Inhibitors for Breast Cancer Market Size by by Players
      • 3.1.1 Global Tubulin Inhibitors for Breast Cancer Revenue by by Players (2014-2019)
      • 3.1.2 Global Tubulin Inhibitors for Breast Cancer Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Tubulin Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI)
    • 3.2 Tubulin Inhibitors for Breast Cancer Key Players Head office and Area Served
    • 3.3 Key Players Tubulin Inhibitors for Breast Cancer Product/Solution/Service
    • 3.4 Date of Enter into Tubulin Inhibitors for Breast Cancer Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Tubulin Inhibitors for Breast Cancer Market Size by Type (2014-2019)
    • 4.2 Global Tubulin Inhibitors for Breast Cancer Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
    • 5.2 Tubulin Inhibitors for Breast Cancer Key Players in United States
    • 5.3 United States Tubulin Inhibitors for Breast Cancer Market Size by Type
    • 5.4 United States Tubulin Inhibitors for Breast Cancer Market Size by Application

    6 Europe

    • 6.1 Europe Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
    • 6.2 Tubulin Inhibitors for Breast Cancer Key Players in Europe
    • 6.3 Europe Tubulin Inhibitors for Breast Cancer Market Size by Type
    • 6.4 Europe Tubulin Inhibitors for Breast Cancer Market Size by Application

    7 China

    • 7.1 China Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
    • 7.2 Tubulin Inhibitors for Breast Cancer Key Players in China
    • 7.3 China Tubulin Inhibitors for Breast Cancer Market Size by Type
    • 7.4 China Tubulin Inhibitors for Breast Cancer Market Size by Application

    8 Japan

    • 8.1 Japan Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
    • 8.2 Tubulin Inhibitors for Breast Cancer Key Players in Japan
    • 8.3 Japan Tubulin Inhibitors for Breast Cancer Market Size by Type
    • 8.4 Japan Tubulin Inhibitors for Breast Cancer Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
    • 9.2 Tubulin Inhibitors for Breast Cancer Key Players in Southeast Asia
    • 9.3 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size by Type
    • 9.4 Southeast Asia Tubulin Inhibitors for Breast Cancer Market Size by Application

    10 India

    • 10.1 India Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
    • 10.2 Tubulin Inhibitors for Breast Cancer Key Players in India
    • 10.3 India Tubulin Inhibitors for Breast Cancer Market Size by Type
    • 10.4 India Tubulin Inhibitors for Breast Cancer Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Tubulin Inhibitors for Breast Cancer Market Size (2014-2019)
    • 11.2 Tubulin Inhibitors for Breast Cancer Key Players in Central & South America
    • 11.3 Central & South America Tubulin Inhibitors for Breast Cancer Market Size by Type
    • 11.4 Central & South America Tubulin Inhibitors for Breast Cancer Market Size by Application

    12 International Players Profiles

    • 12.1 Eisai
      • 12.1.1 Eisai Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.1.4 Eisai Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.1.5 Eisai Recent Development
    • 12.2 Bristol-Myers Squibb
      • 12.2.1 Bristol-Myers Squibb Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.2.4 Bristol-Myers Squibb Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.2.5 Bristol-Myers Squibb Recent Development
    • 12.3 Otsuka Pharmaceutical
      • 12.3.1 Otsuka Pharmaceutical Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.3.4 Otsuka Pharmaceutical Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.3.5 Otsuka Pharmaceutical Recent Development
    • 12.4 Hengrui Medicine
      • 12.4.1 Hengrui Medicine Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.4.4 Hengrui Medicine Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.4.5 Hengrui Medicine Recent Development
    • 12.5 Sanofi
      • 12.5.1 Sanofi Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.5.4 Sanofi Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.5.5 Sanofi Recent Development
    • 12.6 Qilu Pharma
      • 12.6.1 Qilu Pharma Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.6.4 Qilu Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.6.5 Qilu Pharma Recent Development
    • 12.7 Shenzhen Main Luck Pharma
      • 12.7.1 Shenzhen Main Luck Pharma Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.7.4 Shenzhen Main Luck Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.7.5 Shenzhen Main Luck Pharma Recent Development
    • 12.8 Jiangsu Aosaikang Pharma
      • 12.8.1 Jiangsu Aosaikang Pharma Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.8.4 Jiangsu Aosaikang Pharma Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.8.5 Jiangsu Aosaikang Pharma Recent Development
    • 12.9 Genentech
      • 12.9.1 Genentech Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.9.4 Genentech Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.9.5 Genentech Recent Development
    • 12.10 Beijing Biostar Technologies
      • 12.10.1 Beijing Biostar Technologies Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Tubulin Inhibitors for Breast Cancer Introduction
      • 12.10.4 Beijing Biostar Technologies Revenue in Tubulin Inhibitors for Breast Cancer Business (2014-2019)
      • 12.10.5 Beijing Biostar Technologies Recent Development
    • 12.11 Celgene Corporation
    • 12.12 Hospira
    • 12.13 Biological E.
    • 12.14 Taj Accura
    • 12.15 Khandelwal Laboratories
    • 12.16 Luye Pharma
    • 12.17 Beijing Youcare
    • 12.18 Beijing Union
    • 12.19 Haiyao
    • 12.20 Chuntch
    • 12.21 CSPC Pharmaceutical
    • 12.22 Aosaikang Pharm

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Tubulin Inhibitors for Breast Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Tubulin Inhibitors for Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Tubulin Inhibitors for Breast Cancer development in United States, Europe and China.

      The key players covered in this study
      Eisai
      Bristol-Myers Squibb
      Otsuka Pharmaceutical
      Hengrui Medicine
      Sanofi
      Qilu Pharma
      Shenzhen Main Luck Pharma
      Jiangsu Aosaikang Pharma
      Genentech
      Beijing Biostar Technologies
      Celgene Corporation
      Hospira
      Biological E.
      Taj Accura
      Khandelwal Laboratories
      Luye Pharma
      Beijing Youcare
      Beijing Union
      Haiyao
      Chuntch
      CSPC Pharmaceutical
      Aosaikang Pharm

      Market segment by Type, the product can be split into
      Eribulin
      Ixabepilone
      Docetaxel
      Trastuzumab Emtansine
      Utidelone
      Paclitaxel
      Liposome Paclitaxel
      Protein-bound Paclitaxel

      Market segment by Application, split into
      Hospital
      Clinic
      Drug Center
      Other

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Tubulin Inhibitors for Breast Cancer status, future forecast, growth opportunity, key market and key players.
      To present the Tubulin Inhibitors for Breast Cancer development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Tubulin Inhibitors for Breast Cancer are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now